Biowaiver monographs for immediate release solid oral dosage forms: Ciprofloxacin hydrochloride

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 22-33

  Olivera, M E ^a   Manzo, R H ^a   Junginger, H E ^b   Midha, K K ^c   Shah, V P ^d   Stavchansky, S ^e   Dressman, J B ^f   Barends, D M ^g  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b NARESUAN UNIVERSITY   (Thailand)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d International Pharmaceutical Federation FIP   (Netherlands)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f GOETHE UNIVERSITY   (Germany)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Biopharmaceutics classification system (BCS); Ciprofloxacin; Dissolution; Permeability; Regulatory science; Solubility

Indexed keywords

CIPROFLOXACIN; EXCIPIENT;

ARTICLE; BIOEQUIVALENCE; BOOK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; NONHUMAN;

EID: 78650060225     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22259     Document Type: Article

References (94)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Möller H, Olling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93: 1945-1956.
2. Cipro® (ciprofloxacin hydrochloride tablets) Cipro® (ciprofloxacin*) oral suspension. Food and drug administration. (accessed 12-28-2009).
3. Cipro® medication guide, revised October 2008. Bayer health care under lincence of schering corporation. (accessed 12-28-2009).
4. Ciprofloxacin. In clinical pharmacology [on line, restricted access] Gold Standard/ Elsevier (updated 2006 July 11th, accessed 2008 Nov 22). Available from: .
5. Dharnidharka VR, Nadeau K, Cannon CL, Harris HW, Rosen S. 1998. Ciprofloxacin overdose: Acute renal failure with prominent apoptotic changes. Am J Kidney 31: 710-712.
6. Montagnac R, Briat C, Schillinger F, Sartelet H, Birembaut P, Daudon M. 2005. Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin. Nephrol Ther 1: 44-51.
7. Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G. 2007. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 50: 330-335.
8. Bailey JR, Trott SA, Philbrick JT. 1992. Ciprofloxacin-induced acute interstitial nephritis. Am J Nephrol 12: 271-273.
9. USP 32-NF 27. 2009. The United States pharmacopeia -The National Formulary. Rockville, MD: The United States Pharmacopeial Convention, Inc.
10. European Directorate for the Quality of Medicines & HealthCare. 2008. European Pharmacopoeia, 6th edition. Strasbourg, France: Council of Europe.
11. Allemandi DA, Alovero F, Manzo RH. 1999. Formulation of a neutral solution of ciprofloxacin upon complexation with aluminum. Farmaco [Prat] 54: 758-760.
12. Olivera ME, Bistoni A, Anun H, Salinas A, Manzo RH. 2004. Ototopic ciprofloxacin in a glycerin vehicle for the treatment of acute external otitis. Ear Nose Throat J 83: 625-626 628, 630 passim.
13. Manzo RH, Mazzieri MR, Olivera ME. 2005. Preparación de complejos en estado sólido de clorhidratos de antimicrobianos fluoroquiolónicos (AMFQs) con aluminio. Argentinian Patent AR007762B1.
14. Escribano E, Calpena AC, Garrigues TM, Freixas J, Domenech J, Moreno J. 1997. Structure-absorption relationships of a series of 6-fluoroquinolones. Antimicrob Agents Chemother 41: 1996-2000.
15. Sun J, Sakai S, Tauchi Y, Deguchi Y, Chen J, Zhang R, Morimoto K. 2002. Determination of lipophilicity of two quinolone antibacterials, ciprofloxacin and grepafloxacin, in the protonation equilibrium. Eur J Pharm Biopharm 54: 51-58.
16. Vázquez JL, Berlanga M, Merino S, Domènech O, Viñas M, Montero MT, Hernández-Borrell J. 2001. Determination by fluorimetric titration of the ionization constants of ciprofloxacin in solution and in the presence of liposomes. Photochem Photobiol 73: 14-19.
17. Tsuji A, Sato H, Kume Y, Tamai I, Okezaki E, Nagata O, Kato H. 1988. Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother 32: 190-194.
18. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1: 85-96.
19. Romañuk CB. Caracterización Biofarmacéutica y Farmacotécnica de Derivados Farmacéuticos de Anticrobianos Fluoroquinolónicos. [Master Thesis]. Córdoba-Argentina, Universidad Nacional de Córdoba.
20. pION INC, 2003 pION INC, 2003. Molecule of the Month-Ciprofloxacin.HCl. (Accessed 09-10-2008).
21. Fallati C, Ahumada A, Manzo R. 1994. El perfil de solubilidad de la ciprofloxacina en función del pH. Acta Farm Bon 13: 73-77.
22. Romañuk CB, Garro Linck Y, Chattah AK, Monti GA, Manzo RH, Olivera ME. 2009. Characterization of the solubility and solid-state properties of saccharin salts of fluoroquinolones. J Pharm Sci 98: 3788-3801.
23. Yu X, Zipp GL, Davison GWR III. 1994. The effect of temperature and pH on the solubility of quinolone compounds: Estimation of heat of fusion. Pharm Res 11: 522-527.
24. Martindale. 1996. The extra pharmacopoeia, 31st edition. London, UK: Royal Pharmaceutical Society.
25. [15th] Essential Medicines WHO Model List (revised March 2007). .
26. Administración Nacional de Medicamentos, Alimentos y Tecnología Médica de la República Argentina ANMAT. (assessed 12/21/2009).
27. Rote Liste ® Arzneimittelsverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Service GmbH Frankfurt/Main:. (accessed 06-06-2008).
28. Laegemiddel Styrelson Danish Medicines Agency. (accessed 06-09-2008).
29. National Agency for Medicines, Helsinki, Finland: The National Agency for Medicines responsibilities are to maintain and promote the safety and safe use of medicinal products, medical devices and blood products. (accessed 06-11-2008).
30. VIDAL L'information de référence sur les produits de santé. (accessed 06-11-2008).
31. College ter Beoordeling van Geneesmiddelen-Medicines Evaluation Board of The Netherlands. (accessed 06-06-2008).
32. Statens legemiddelverk, Norvegian Medicines Agency. (accessed 06-11-2008).
33. Agencia Española de, Medicamentos y Productos Sanitarios. (accessed 03-03-2008).
34. Läkemedelsverket Medical Product Agency, Sweden. (accessed 06-12-2008).
35. The medicines information web site provided by Datapharm Communications Ltd. (accessed 06-12-2008).
36. U.S. National library of medicine. Daily Med current medication information. National Institutes of Health, Health & Human Services. (accessed 06-12-2008).
37. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. 1986. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother 30: 444-446.
38. Brunner M, Sta H, Moller JG, Schrolnberger C, Erovic B, Hollenstein U, Zeitlinger M, Eichler HG, Muller M. 2002. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 46: 3724-3730.
39. Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P. 1985. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 27: 375-379.
40. Plaisance KI, Drusano GL, Forrest A, Bustamante C, Standiford HC. 1987. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 31: 956-958.
41. Tartaglione TA, Raffalovich AC, Poynor WJ, Espinel-Ingroff A, Kerkering TM. 1986. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother 29: 62-66.
42. Hoffler D, Dalhoff A, Gau W, Beermann D, Michl A. 1984. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol 3: 363-366.
43. Ledergerber B, Bettex JD, Joos B, Flepp M, Luthy R. 1985. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 27: 350-352.
44. Shah A, Liu MC, Vaughan D, Heller AH. 1999. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500mg tablet compared with 500mg/10mL or 500mg/5mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension. J Antimicrob Chemother 43: 49-54.
45. Neuhofel AL, Wilton JH, Victory JM, Hejmanowsk LG, Amsden GW. 2002. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: A new twist on an old interaction. J Clin Pharmacol 42: 461-466.
46. Schmidt LE, Dalhoff K. 2002. Food-drug interactions. Drugs 62: 1481-1502.
47. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. 1989. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 33: 1841-1844.
48. Marchbanks CR. 1993. Drug-drug interactions with fluoroquinolones. Pharmacotherapy 13: 23S-28S.
49. Stein GE. 1991. Drug interactions with fluoroquinolones. Am J Med 91: 81S-86S.
50. Zakelj S, Berginc K, Ursic D, Kristl A. 2007. Influence of metal cations on the solubility of fluoroquinolones. Pharmazie 62: 318-320.
51. Tözüm TF, Yildirim A, Çaglayan F, Dinçel A, Jada AB. 2004. Serum and gingival crevicular fluid levels of ciprofloxacin in patients with periodontitis. J Am Dent Assoc 135: 1728-1732.
52. Wise R, Baldwin DR, Andrews JM, Honeybourne D. 1991. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. J Antimicrob Chemother 58: 65-71.
53. Boerema JB, Dalhoff A, Debruyne FM. 1985. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 31: 13-18.
54. Edmiston CE, Suarez EC, Walker AP, Demeure MP, Frantzides CT, Schulte WJ, Wilson SD. 1996. Penetration of ciprofloxacin and fleroxacin into biliary tract. Antimicrob Agents Chemother 40: 787-788.
55. Drusano GL, Plaisance KI, Forrest A, Standiford HC. 1986. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother 30: 440-443.
56. Karabalut N, Drusano GL. 1993. Pharmacokinetics of the quinolone antimicrobial agents. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents, 2nd edition. Washington, DC: American Society for Microbiology. 195-223.
57. Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, Forrest A, Drusano GL. 1985. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother 28: 235-239.
58. Dudley MN, Ericson J, Zinner SH. 1987. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother 31: 1782-1786.
59. Harder S, Fuhr U, Beermann D, Staib H. 1990. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the HF-capsule. Br J Clin Pharmacol 30: 35-39.
60. Volpe DA. 2004. Permeability classification of representative fluoroquinolones by a cell culture method. AAPS Pharm Sci 6: e13.
61. Rodriguez-Ibañez M, Sanchez-Castano G, Montalar-Montero M, Garrigues TM, Bermejo M, Merino V. 2006. Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin. Int J Pharm 307: 33-41.
62. Žakelj S, Šturm K, Kristl A. 2006. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int J Pharm 313: 175-180.
63. Rodríguez-Ibáńez M, Nalda-Molina R, Montalar-Montero M, Bermejo MV, Merino V, Garrigues TM. 2003. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: In vitro and in situ inhibition studies. Eur J Pharm Biopharm 55: 241-246.
64. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R. 1999. Active intestinal elimination of ciprofloxacin in rats: Modulation by different substrates. Br J Pharmacol 127: 1728-1734.
65. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17: 1456-1460.
66. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. 1999. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88: 1067-1072.
67. Azad MAK, Ullah A, Mahbub Latif AHM, Hasnat A. 2007. Bioequivalence and pharmacokinetic study of two oral formulations of ciprofloxacin tablets in healthy male volunteers. J Appl Res 7: 150-157.
68. Maya MT, Gonçalves NJ, Silva NE, Filipe AE, Morais JA. 2003. Bioequivalence evaluation of three different oral formulations of ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 28: 129-136.
69. Harahap Y, Prasaja B, Indriati E, Lusthom W, Lipin 2007. Bioequivalence of ciprofloxacin tablet formulations assessed in Indonesian volunteers. Int J Clin Pharmacol Ther 45: 373-376.
70. Galicia I, Frias-Iniesta J, Carcas AJ, Soto A, Gomez E, Miranda E, Fernandez A, Montuenga C. 1998. Bioequivalence evaluation of 2 different oral formulations of ciprofloxacin in healthy volunteers. Int J Clin Pharmacol Ther 36: 282-285.
71. Hassan Y, Alfadly SO, Azmin MN, Peh KK, Tan TF, Noorizan AA, Ismail O. 2007. Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers. Singapore Med J 48: 819-823.
72. Khan MK, Khan MF. 2008. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. Pak J Pharm Sci 21: 299-306.
73. Abdallah RM, Alam SM, Awaad FM, Dham R, El-Kersh A, El-Laithy A, Shalby MH, Shihabeddin M, El-Walily AF, Yacout M, Zaman Q. 2002. Bioequivalence of two brands of ciprofloxacin 750mg tablets (Sarf and Ciprobay) in healthy human volunteers. Drug Dev Ind Pharm 28: 423-429.
74. Cuadrado A, Gascón AR, Solinís MA, Ramírez E, Hernández RM, Knie U, Pedraz JL. 2004. Bioequivalence of two oral ciprofloxacin tablets formulations. Int J Clin Pharmacol Ther 42: 336-341.
75. US Department of Health and Human Services, Food and Drug Administration, Center for Evaluation and Research (CDER) 2000. Guidances for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. .
76. WHO. 2006. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability, Technical Report Series, No 937, 40th Report, Annex 7 of WHO Expert committee on specifications for pharmaceutical preparations. .
77. European Medicines Evaluation Agency (EMEA), 2001. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. .
78. Tang Y, Gan K. 1998. Statistical evaluation of in vitro dissolution of different brands of ciprofloxacin hydrochloride tablets and capsules. Drug Dev Ind Pharm 24: 549-552.
79. Breda SA, Jimenez Kairuz AF, Manzo RH, Olivera ME. 2009. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. Int J Pharm 371: 106-113.
80. Khan KA. 1975. The concept of dissolution efficiency. J Pharm Pharmacol 27: 48-49.
81. Ofoefule SI, Udeogaranya PO, Okonta JM. 2001. Prediction of in vivo bioavailability of six brands of ciprofloxacin film coated tablets using the concept dissolution efficiency (DE). Boll Chim Farm 140: 187-191.
82. Osadebe PO, Esimone OC, Akabogu IC. 2003. An empirical assessment of the possibility of interchangeability between multisource ciprofloxacin hydrochloride tablets marketed in Nigeria. Boll Chim Farm 142: 352-356.
83. EMEA. 2008. Draft Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev.1. .
84. A theoretical basis for a biopharmaceutic drug classifi{ligature}cation: The correlation of in vitro drug product dissolution and in vivo bioavailability
85. Artursson P, Palm K, Luthaman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 27-43.
86. Rinaki E, Valsami G, Macheras P. 2003. Quantitative biopharmaceutics classification system: The central role of dose/solubility ratio. Pharm Res 20: 1917-1925.
87. Gres M-C, Julian B, Bourre M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. 1998. Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharm Res 15: 726-733.
88. Lindenberg M, Kopp S, Dressman JB. 2004. Classifi{ligature}cation of orally administered drugs on the World Health Organization Model list of essential medicines according to the biopharmaceutics classifi{ligature}cation system. Eur J Pharm Biopharm 58: 265-278.
89. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23.
90. WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert committee on specifications. .
91. Yu LX. 2004. BioINequivalence: Concept and Definition. ACPS Meeting, October 19-20. (accessed 10-25-2009).
92. Gleiter CH, Klotz U, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Müller C, Holz-Slomczyk M. 1998. When are bioavailability studies required? A German proposal. J Clin Pharmacol 38: 904-911.
93. FDA. 2005. Guidance for Industry. Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-IR) .
94. European Commission. 2006. Guideline on Dossier requirements for Type IA and Type IB. .